Analyst Price Target is $80.45
▲ +52.09% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $80.45, with a high forecast of $104.00 and a low forecast of $62.00. The average price target represents a 52.09% upside from the last price of $52.90.
Current Consensus is
Moderate Buy
The current consensus among 11 contributing investment analysts is to moderate buy stock in MoonLake Immunotherapeutics. This rating has held steady since June 2023, when it changed from a Buy consensus rating.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More